Wiseman JT, et al. - Researchers investigated whether neoadjuvant systemic chemotherapy contributes to clinically significant increases in postoperative morbidity and mortality via analyzing patients with colorectal liver metastases (CRLM) who underwent liver resection from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Targeted Hepatectomy Participant Use Files from 2014-2016. After propensity score matching, neoadjuvant chemotherapy prior to hepatectomy was received by 1,416 patients (50%) and liver resection without neoadjuvant chemotherapy was done on 1,416 (50%). Outcomes revealed no higher rates of complications, biliary fistula, post-hepatectomy liver failure, or mortality in correlation to the use of neoadjuvant systemic chemotherapy among these patients.